Cardiac Markers in Depressed Patients With Coronary Heart Disease - R01HL147862

Description

Depression doubles the risk of death in patients with coronary heart disease (CHD), but so far, there is insufficient evidence that we can reduce the risk of death by treating depression. This study will investigate the cardiac risk markers that are associated with depression symptoms that remain despite treatment, and identify potential targets for their treatment. The results of the study will inform the development of more effective interventions to improve both depression and survival in patients with CHD.

Conditions

Coronary Heart Disease, Depression

Talk to us

Study Overview

On this page

Study Details

Study overview

Depression doubles the risk of death in patients with coronary heart disease (CHD), but so far, there is insufficient evidence that we can reduce the risk of death by treating depression. This study will investigate the cardiac risk markers that are associated with depression symptoms that remain despite treatment, and identify potential targets for their treatment. The results of the study will inform the development of more effective interventions to improve both depression and survival in patients with CHD.

Fatigue, Anhedonia and Cardiac Prognostic Markers in Depressed Patients With Coronary Heart Disease

Cardiac Markers in Depressed Patients With Coronary Heart Disease - R01HL147862

Condition
Coronary Heart Disease
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University, Saint Louis, Missouri, United States, 63108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients seen at the Washington University Medical Center with coronary heart disease (CHD) documented by coronary angiography or history of acute coronary syndrome (ACS).
  • * On a stable medication regimen (only minor changes in drug or dosage in last 30 days) are eligible for recruitment.
  • * Meet the diagnostic criteria for a depressive disorder, score ≥ 14 on the Beck Depression Inventory (BDI-II), and not meet any exclusion criteria.
  • * Thyroid disease or thyroid medications.
  • * Moderate to severe cognitive impairment.
  • * Major psychiatric comorbidities.
  • * Taking antidepressants other than a selective serotonin reuptake inhibitor (SSRI).
  • * Suicidal features.
  • * Current substance abuse.
  • * New York Heart Association (NYHA) class III or higher or a recent (\<3 months) acute coronary syndrome (ACS), coronary artery bypass graft surgery, cardiac hospitalization, or cardiac-related emergency department visit.
  • * Advanced malignancy, a disability that would prevent compliance with the study protocol, or physician or patient refusal.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Washington University School of Medicine,

Kenneth E Freedland, PhD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

2025-05-31